Filing Flows

Filing Flows › Health Care › Cardiff Oncology (CRDF)

Cardiff Oncology (CRDF) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 11, 2026 · Cardiff Oncology (CRDF) Q2 2026 earnings results →

Q2 2026 Revenue down 14% year over year to $104K

Cardiff Oncology made $104K in Q2 2026 (-14% Y/Y). Operating margin n/m, net loss $9.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 11, 2026.

Revenue$104K
Year over year-14%
Operating marginn/m
Net earnings−$9.2M
Operating cash flow−$11.8M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $104K in Q2 2026, down 14% year over year and up 154% from the previous quarter.

Operating costs exceeded revenue by $9.6M, an operating margin of -9245.2%. Total costs fell 35% while revenue fell 14%. The fastest-growing cost line was SG&A (+15%). The quarter ended with a net loss of $9.2M, narrower than the previous quarter's $12.3M loss.

Operating cash flow was −$11.8M. Non-cash charges added back $87K of depreciation and $920K of share-based compensation. Working capital and other items used $3.5M.

Quarterly history

Cardiff Oncology revenue by quarterCardiff Oncology revenue by quarter$151KQ4 2024$109KQ1 2025$121KQ2 2025$120KQ3 2025$243KQ4 2025$41KQ1 2026$104KQ2 2026
Cardiff Oncology net earnings by quarterCardiff Oncology net earnings by quarter−$11.8MQ4 2024−$13.4MQ1 2025−$13.9MQ2 2025−$11.3MQ3 2025−$7.2MQ4 2025−$12.3MQ1 2026−$9.2MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 11, 2026$104K-14%n/m−$9.2M−$11.8M
Q1 202610-QMay 14, 2026$41K-62%n/m−$12.3M−$12.3M
Q4 202510-KFeb 24, 2026$243K+61%n/m−$7.2M−$6.0M
Q3 202510-QNov 6, 2025$120K-27%n/m−$11.3M−$10.8M
Q2 202510-QJul 29, 2025$121K-26%n/m−$13.9M−$8.3M
Q1 202510-QMay 8, 2025$109K-47%n/m−$13.4M−$12.8M
Q4 202410-KFeb 27, 2025$151K-3%n/m−$11.8M−$10.3M

Charts

Cardiff Oncology: revenue growth, year over year and quarter over quarterCardiff Oncology: revenue growth, year over year and quarter over quarterY/YQ/Q-3%Q4 2024-47%-28%Q1 2025-26%+11%Q2 2025-27%-1%Q3 2025+61%+102%Q4 2025-62%-83%Q1 2026-14%+154%Q2 2026
Latest (Q2 2026): Y/Y -14%, Q/Q +154%.
Cardiff Oncology: where the cash came from (+) and went (−), TTM to Q2 2026Cardiff Oncology: where the cash came from (+) and went (−), TTM to Q2 2026Operating cash flow−$40.9MOther investing$36.5MOther financing$2.0MCash drawn (+) / kept (−)$1.6MShares issued$808KCapital spending−$62K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Cardiff Oncology: profit against cash, quarter by quarterCardiff Oncology: profit against cash, quarter by quarterNet incomeOperating cash flow−$11.9M−$10.5MQ3 2024−$11.8M−$10.3MQ4 2024−$13.4M−$12.8MQ1 2025−$13.9M−$8.3MQ2 2025−$11.3M−$10.8MQ3 2025−$7.2M−$6.0MQ4 2025−$12.3M−$12.3MQ1 2026−$9.2M−$11.8MQ2 2026
Latest (Q2 2026): Net income −$9.2M, Operating cash flow −$11.8M.
Cardiff Oncology: diluted shares by fiscal year (split-adjusted)Cardiff Oncology: diluted shares by fiscal year (split-adjusted)42MFY202039MFY202144MFY202245MFY202348MFY202467MFY2025
+60.1% since FY2020: more shares outstanding (issuance, stock pay); earlier years scaled for the 2-for-1 split before FY2021.
Cardiff Oncology in its industry: growth against margin (76 companies, SIC 2836)Cardiff Oncology in its industry: growth against margin (76 companies, SIC 2836)revenue growth, year over year →↑ operating marginmedian +9%median -100%AMGNGILDBIIBMRNANBIXEXELHALOMGTXTECHVIRRGENTARSBCRXALECADMAKRYSIOVATWSTIPSCIMCRVISKVCELADPTNVAXKYMRGLUEIBRXAUTLAGENDNAPLXRXRXFENCCSBRCHRSIVVDCRSPEDITDTILVXRTSTRORGNXCCCCBSEMSCLXACOGTSHASRZNVYGRFDMTLENZALGSXFORELUTFATEOCGNSCTXCRBUCGONDBVTINBXMGXLCTXTCRXDYAIPRMEATRAVitro Biopharma, Inc.HUMARLAYPLURBEAMPROKAIMVIVSCRDF (-14%, -100%)
Biological Products, (No Diagnostic Substances); dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Cardiff Oncology

We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics. We are focusing our clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), metastatic triple negative breast cancer ("mTNBC") and Chronic Myelomonocytic Leukemia ("CMML"). Our clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment.

In its own words, from its 10-K, filed Feb 24, 2026.

Cardiff Oncology against its Biological Products, (No Diagnostic Substances) peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -14% against the peers' median +11%.

CompanyQuarterRevenueY/YOp. margin
CRDF Cardiff OncologyQ2 2026$104K-14%n/m
AMGN AmgenQ3 2026$10.4B+8%35.8%
GILD Gilead SciencesQ3 2026$8.3B+7%41.7%
BIIB BiogenQ3 2026$2.8B+11%-0.3%
MRNA ModernaQ3 2026$1.3B+29%9.9%
NBIX Neurocrine BiosciencesQ3 2026$1.1B+41%29.5%
EXEL ExelixisQ3 2026$659M+10%40.8%
HALO Halozyme TherapeuticsQ3 2026$493M+39%59.8%
MGTX MeiraGTx HoldingsQ2 2026$321M87×76.0%

Source: Cardiff Oncology 10-Q on SEC EDGAR · CIK 1213037 · Biological Products, (No Diagnostic Substances)

13F: who owns CRDF and who is buying

Largest holders of CRDF (13F)Largest holders of CRDF (13F)Vanguard Group$10.5MVanguard Capital Management LLC$3.8MLaurion Capital Management LP$3.7MPfizer$3.0MFranklin Resources$1.6MBlackRock$1.3MBlair William$1.2MGeode Capital Management, LLC$1.1MGoalVest Advisory LLC$832KUBS Group AG$830K
Funds' net buying of CRDF by quarter (13F)Funds' net buying of CRDF by quarter (13F)$647K2024-09$32.2M2024-12$12.5M2025-03−$10.8M2025-06−$9.0M2025-09$6.2M2025-12−$4.4M2026-03−$7.6M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on CRDF

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare CRDF with

中文版：Cardiff Oncology（CRDF）财报

Español · Français